Geode Capital Management
DSGN icon

Geode Capital Management’s Design Therapeutics DSGN Stock Holding History

Geode Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9M Buy
958,417
+265,899
+38% +$3.32M ﹤0.01% 2359
2026
Q1 		$7.37M Buy
692,518
+12,928
+2% +$131K ﹤0.01% 2547
2025
Q4 		$6.38M Sell
679,590
-16,023
-2% -$125K ﹤0.01% 2643
2025
Q3 		$5.24M Sell
695,613
-98,395
-12% -$493K ﹤0.01% 2753
2025
Q2 		$2.68M Buy
794,008
+18,511
+2% +$69.3K ﹤0.01% 3040
2025
Q1 		$2.99M Buy
775,497
+13,857
+2% +$66.1K ﹤0.01% 2886
2024
Q4 		$4.7M Buy
761,640
+3,090
+0.4% +$17.9K ﹤0.01% 2777
2024
Q3 		$4.08M Buy
758,550
+50,579
+7% +$238K ﹤0.01% 2869
2024
Q2 		$2.37M Buy
707,971
+24,073
+4% +$93.8K ﹤0.01% 3077
2024
Q1 		$2.76M Buy
683,898
+21,154
+3% +$56.5K ﹤0.01% 2987
2023
Q4 		$1.76M Buy
662,744
+28,024
+4% +$64.2K ﹤0.01% 3154
2023
Q3 		$1.5M Sell
634,720
-2,125
-0.3% -$9.91K ﹤0.01% 3175
2023
Q2 		$4.01M Buy
636,845
+3,837
+0.6% +$23.5K ﹤0.01% 2811
2023
Q1 		$3.65M Buy
633,008
+29,995
+5% +$224K ﹤0.01% 2771
2022
Q4 		$6.19M Buy
603,013
+26,304
+5% +$356K ﹤0.01% 2546
2022
Q3 		$9.64M Buy
576,709
+141,584
+33% +$2.82M ﹤0.01% 2290
2022
Q2 		$6.09M Buy
435,125
+68,380
+19% +$924K ﹤0.01% 2590
2022
Q1 		$5.92M Buy
366,745
+15,304
+4% +$234K ﹤0.01% 2703
2021
Q4 		$7.52M Buy
351,441
+93,409
+36% +$1.6M ﹤0.01% 2641
2021
Q3 		$3.79M Buy
258,032
+5,272
+2% +$87.6K ﹤0.01% 3069
2021
Q2 		$5.03M Buy
252,760
+215,060
+570% +$5.43M ﹤0.01% 2906
2021
Q1 		$1.13M Buy
+37,700
New +$1.27M ﹤0.01% 3503

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management's DSGN Position: Q2 2026 in Review

Geode Capital Management increased its Design Therapeutics (DSGN) stake by 38% in Q2 2026, buying an estimated $3.32M and bringing the position to 958,417 shares worth $13.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2359.

Geode Capital Management first reported a position in DSGN in Q1 2021 and has held it in 22 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Geode Capital Management held 958,417 shares of Design Therapeutics worth $13.9M as of Q2 2026.
  • Geode Capital Management bought 265,899 Design Therapeutics shares in Q2 2026, an estimated $3.32M.
  • Design Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2359 holding.
  • Geode Capital Management first reported a position in Design Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.